Program: Education Program
Session: Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation
Hematology Disease Topics & Pathways:
Research, Antibody Therapy, Clinical Research, Education, Diseases, Immune Disorders, Treatment Considerations, Biological therapies, Lymphoid Malignancies
	
	
	
		Session: Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation
Hematology Disease Topics & Pathways:
Research, Antibody Therapy, Clinical Research, Education, Diseases, Immune Disorders, Treatment Considerations, Biological therapies, Lymphoid Malignancies
Saturday, December 7, 2024, 9:30 AM-10:45 AM
		
	
	
	
	
	
	Disclosures: Chen: Recordati: Honoraria, Speakers Bureau; GlaxoSmithKline: Honoraria.
OffLabel Disclosure: off label use of B cell depletion therapy (rituximab, obexelimab) will be discussed as IgG4-RD is a rare disease.
	See more of: Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation 
See more of: Education Program
	
	
					See more of: Education Program
 
	
	 denotes an abstract that is clinically relevant.
 denotes an abstract that is clinically relevant. denotes that this is a recommended PHD Trainee Session.
 denotes that this is a recommended PHD Trainee Session. denotes that this is a ticketed session.
 denotes that this is a ticketed session.